Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290196 · ClinicalTrials.gov registry record · Phase 4
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
A Phase 4 study, sponsored by Andrews Research & Education Foundation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT03290196: Clinical Trial Phase 4 study, sponsored by Andrews Research & Education Foundation.
NCT03290196 is a Phase 4 study that was terminated before completion, run by Andrews Research & Education Foundation. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290196, a Phase 4 study, was terminated before completion, sponsored by Andrews Research & Education Foundation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
Patients undergoing shoulder rotator cuff surgery in an outpatient setting are the focus of this study. The purpose of this study is to determine if the product EXPAREL® can be used as a safe alternative in shoulder surgery to pain pumps, while limiting narcotic use and providing appropriate postoperative pain control.
Primary Outcome
Patient reported numeric pain rating using visual analog scale (VAS) (0 = none, 10 = severe)
Interventions
- DRUG EXPAREL 1.3 % in 20 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2022-04-07 |
| Phase | Phase 4 |
Why NCT03290196 stopped before completion
NCT03290196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which EXPAREL 1.3 % in 20 ML Injection is the first listed.
NCT03290196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03290196 about?
NCT03290196 is a clinical study titled "The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics". Patients undergoing shoulder rotator cuff surgery in an outpatient setting are the focus of this study. The purpose of this study is to determine if the product EXPAREL® can be used as a safe alternative in shoulder surgery to pain pumps, while limiting narcotic use and providing appropriate postope...
What is the current status of trial NCT03290196?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2015-09-03. Estimated completion is 2022-04-07.
What interventions are being tested in trial NCT03290196?
The interventions under investigation include: EXPAREL 1.3 % in 20 ML Injection (DRUG).
Who is sponsoring clinical trial NCT03290196?
This trial is sponsored by Andrews Research & Education Foundation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03290196's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI